An Uncommon Insertion Mutation in Exon 19 of EGFR Showed Stable Disease after TKI Treatment
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Ins19 accounts for 0.6% (26/4519) of EGFR mutations.
“Ins19 is a subset accounting for 0.6% (26/4519).28, 48, 82, 83”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
He, M., Capelletti, M., Nafa, K., Yun, C.-H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2361 · Cited by 149 · see citing works
Otto, C., Csanádi, Á., Fisch, P., Werner, M., & Kayser, G. (2012) · Diagnostic Pathology · doi:10.1186/1746-1596-7-146 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Kobayashi, Y., & Mitsudomi, T. (2016) · Cancer Science · doi:10.1111/cas.12996 · Cited by 413 · see citing works
Lin, Y.-T., Liu, Y.-N., Wu, S.-G., Yang, J. C.-H., & Shih, J.-Y. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.12.014 · Cited by 43 · see citing works
- Authors
- Chan, A. W. H., Tong, J. H. M., Lo, S.-H., & To, K. F.
- Affiliations
- Chinese University of Hong Kong (HK)
- Tuen Mun Hospital (CN)
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 8
- Issue
- 12
- Pages
- e107-e108
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2004079382
- Cited by
- 9
- References
- 2
- Citations by year
- 2025: 2 · 2023: 1 · 2018: 1 · 2017: 1 · 2016: 3 · 2014: 1
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- lung adenocarcinoma, metastatic lung cancer, tyrosine kinase inhibitor therapy, stable disease, EGFR mutation, non-small cell lung cancer
- MeSH terms
- Erlotinib Hydrochloride, Adenocarcinoma, Exons, Female, Humans, Lung Neoplasms, Middle Aged, Mutation, Prognosis, Quinazolines, Mutagenesis, Insertional, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
